Analysis of Mortality Rates from Cardiovascular Diseases in Different Regions of Panama and Associated Risk Factors

Authors

  • Mary Carmen Yànguez Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Charybeth Chavarrìa Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Sahara Medina Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Mixaida Castillo Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Cynthia Cepeda Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Iris Griffith Griffith Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Sergio Real Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Yiseila Franco Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Rosa Albaez Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.
  • Sharming L. Gonzàlez Fundación Social, Educativa y Cultural del Claustro Gómez. Chiriquí, Panamá.

Keywords:

Personalized treatment, Early diagnosis, Human genome and heart diseases, Cardiovascular prevention, Cardiovascular diseases

Abstract

Cardiovascular diseases are the leading cause of death in developed countries. The challenges faced by experts worldwide to halt the progression of what they already consider an epidemic are directed in four areas: prevention, diagnosis, treatment, and research. In this article, the author reviews some of the new perspectives in the treatment of cardiovascular system diseases. Many cardiac diseases are silent. 50% of males and 64% of females die suddenly due to heart disease, without prior warning. Experts believe that determining the risk as early and accurately as possible is crucial. In this context, it is essential to know who and why someone might have a heart attack. Part of the answer lies in our genes. Tracking the human genome to identify genes involved in heart diseases and developing a routine test to calculate a person's genetic sensitivity could be decisive in controlling these diseases. Understanding our genetic predisposition, reviewing patient habits, weight, blood pressure, and known risk factors such as cholesterol levels, among others, will enable doctors to determine more precisely and convincingly which patients need pharmacological treatment with statins, which patients only need to increase exercise, or which patients must definitively change their lifestyle before a cardiovascular episode occurs.

References

2001-2013., S. d. (s.f.). nfermedades Cardiovasculares y Diabetes en la República de Panamá. Años 2001-2013. En S. d. 2001-2013..

Chardiet, A. F. (2017). Categoría de riesgo de enfermedad cardiovascular. Revista Cubana de Medicina General Integral.

Direcciòn Nacional de Planificaciòn, Departamento de Estadìstica y Salud. (2021). En Torrades.

Encuesta Nacional de Salud y Calidad de Vida 2020. (2020).

Enfermedades cardiovasculares. (2022). En OMS.

Gorgas, I. C. (2023). Direcciòn de investigaciòn. . Panamà.

Salud, O. M. (2023). Iniciativa Global Hearts.

Salud, O. P. (2023). HEARTS en las Américas.

Torrades, S. (2021). Retos para detener una epidemia silenciosa. En S. Torrades.

Published

2024-02-10

How to Cite

Yànguez, M. C. ., Chavarrìa, C. ., Medina, S. ., Castillo, M. ., Cepeda, C. ., Griffith, I. G., Real, S. ., Franco, Y. ., Albaez, R. ., & Gonzàlez , S. L. . (2024). Analysis of Mortality Rates from Cardiovascular Diseases in Different Regions of Panama and Associated Risk Factors. Multidisciplinary &Amp; Health Education Journal, 6(1), 798–807. Retrieved from http://journalmhe.org/ojs3/index.php/jmhe/article/view/111